Rituximab: modes of action, remaining dispute and future perspective
Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of o...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
Future Medicine Ltd.
2014
|
| Subjects: | |
| Online Access: | http://eprints.utm.my/id/eprint/62489/ http://dx.doi.org/10.2217/fon.14.146 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|